ECSP22016630A - Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina - Google Patents

Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina

Info

Publication number
ECSP22016630A
ECSP22016630A ECSENADI202216630A ECDI202216630A ECSP22016630A EC SP22016630 A ECSP22016630 A EC SP22016630A EC SENADI202216630 A ECSENADI202216630 A EC SENADI202216630A EC DI202216630 A ECDI202216630 A EC DI202216630A EC SP22016630 A ECSP22016630 A EC SP22016630A
Authority
EC
Ecuador
Prior art keywords
triazol
elaboration
orexin receptor
synthetic methods
receptor modulators
Prior art date
Application number
ECSENADI202216630A
Other languages
English (en)
Inventor
Florian Damien Medina
Dominique Paul Michel Depre
Pieter Westerduin
Cheng Yi Chen
Kiran Matcha
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP22016630A publication Critical patent/ECSP22016630A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/16—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of hydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen procesos para preparar (((3aR,6aS)-5-(4,6-dimetilpirimidin-2-il)hexahidropirrolo[3,4-c]pirrol-2(1H)-il)(2-fluoro-6-(2H-1,2,3-triazol-2-il)fenil)metanona, que son útiles para la fabricación comercial. Dicho compuesto es un modulador del receptor de orexina y puede ser útil en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos y afecciones mediadas por la actividad de la orexina, tales como el insomnio y la depresión.
ECSENADI202216630A 2019-08-07 2022-03-04 Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina ECSP22016630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883857P 2019-08-07 2019-08-07
US202062971265P 2020-02-07 2020-02-07

Publications (1)

Publication Number Publication Date
ECSP22016630A true ECSP22016630A (es) 2022-04-29

Family

ID=72139573

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202216630A ECSP22016630A (es) 2019-08-07 2022-03-04 Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina

Country Status (15)

Country Link
US (1) US20220289754A1 (es)
EP (1) EP4010325A1 (es)
JP (1) JP2022543286A (es)
KR (1) KR20220044323A (es)
CN (1) CN114555603A (es)
AU (1) AU2020324552A1 (es)
BR (1) BR112022002128A2 (es)
CA (1) CA3149689A1 (es)
CR (1) CR20220050A (es)
EC (1) ECSP22016630A (es)
IL (1) IL290362A (es)
JO (1) JOP20220031A1 (es)
MX (1) MX2022001615A (es)
PE (1) PE20220842A1 (es)
WO (1) WO2021023843A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
DK2491038T3 (da) * 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
US8299117B2 (en) * 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
JP6464190B2 (ja) * 2014-04-01 2019-02-06 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 複素環化合物の線虫防除のための使用

Also Published As

Publication number Publication date
KR20220044323A (ko) 2022-04-07
JOP20220031A1 (ar) 2023-01-30
EP4010325A1 (en) 2022-06-15
CR20220050A (es) 2022-04-20
WO2021023843A1 (en) 2021-02-11
PE20220842A1 (es) 2022-05-24
JP2022543286A (ja) 2022-10-11
CN114555603A (zh) 2022-05-27
CA3149689A1 (en) 2021-02-11
MX2022001615A (es) 2022-05-26
AU2020324552A1 (en) 2022-03-24
US20220289754A1 (en) 2022-09-15
IL290362A (en) 2022-04-01
BR112022002128A2 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
ECSP21034253A (es) Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina
ECSP19047936A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
SV2018005800A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
CR20120273A (es) OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO MODULADORES DEL RECEPTOR DE OREXINA
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
CR20190282A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
BR112016000195A8 (pt) compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
WO2011149950A3 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
WO2010068483A3 (en) Mlk inhibitors and methods of use
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
NI202000100A (es) Inhibidores de moléculas pequeñas de la familia de quinasa jak
PE20212196A1 (es) Compuestos, composiciones, y metodos para modular la actividad cdk9
BR112018013763A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilclona m4
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
ECSP22016630A (es) Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina
MX2024005097A (es) Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneracion de tejidos, organogenesis y funcion para multiples tejidos.
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
MX2024005884A (es) Usos de compuestos biciclicos para el tratamiento de enfermedades.
MX2024005997A (es) Antagonistas del receptor de adenosina.
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases